

**7 January 2022**

**ASX Announcement**

**RETRACTION OF COMPARISON SLIDE**

**MELBOURNE Australia, 7 January 2022:** AdAlta Limited (ASX:1AD), the clinical stage biotechnology company developing novel therapeutic products from its i-body platform released presentations on 15 December 2021 titled '*Cash Position and Corporate Presentation*' and on 4 January 2022 titled '*Presentation Conference Schedule - January 2022*'.

The presentations contained information relating to the potential future value of the Company's strategy on page 26 (slide 23 of the presentation) of the 15 December 2021 ASX announcement and page 21 (slide 19 of the presentation) of the 4 January 2022 ASX announcement.

Following consultation with the ASX, the Company wishes to retract the material on those slides and inform investors that they should not rely on that information as the basis for any investment decision.

Authorised for lodgement by:

**Tim Oldham**  
**CEO and Managing Director**  
**January 2022**

**Notes to editor**

**About AdAlta**

AdAlta Limited is a clinical stage drug development company headquartered in Melbourne, Australia. The Company is using its proprietary i-body technology platform to solve challenging drug targeting problems and generate a promising new class of single domain antibody protein therapeutics with the potential to treat some of today's most challenging medical conditions.

The i-body technology mimics the shape and stability of a unique and versatile antigen binding domain that was discovered initially in sharks and then developed as a human protein. The result is a range of unique proteins capable of interacting with high selectivity, specificity and affinity with previously difficult to access targets such as G-protein coupled receptors (GPCRs) that are implicated in many serious diseases. i-bodies are the first fully human single domain antibody scaffold and the first based on the shark motif to reach clinical trials.

AdAlta has completed Phase I clinical studies for its lead i-body candidate, AD-214, that is being developed for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases for which current therapies are sub-optimal and there is a high unmet medical need.



The Company is also entering collaborative partnerships to advance the development of its i-body platform. It has an agreement with GE Healthcare to co-develop i-bodies as diagnostic imaging agents against Granzyme B, a biomarker of response to immuno-oncology drugs, a program now in preclinical development. It also has a collaboration with Carina Biotech to co-develop precision engineered, i-body enabled CAR-T cell therapies to bring new hope to patients with cancer.

AdAlta's strategy is to maximise the products developed using its next generation i-body platform by internally discovering and developing selected i-body enabled product candidates against GPCRs implicated in fibrosis, inflammation and cancer and partnering with other biopharmaceutical companies to develop product candidates against other classes of receptor, in other indications, and in other product formats.

Further information can be found at: <https://adalta.com.au>

**For more information, please contact:**

**Investors**

Tim Oldham, CEO & Managing Director  
Tel: +61 403 446 665  
E: [t.oldham@adalta.com.au](mailto:t.oldham@adalta.com.au)

**Media**

IR Department  
Tel: +61 411 117 774  
E: [jane.lowe@irdepartment.com.au](mailto:jane.lowe@irdepartment.com.au)